Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS. The medicines are the first to slow the disease, which may give people extra ...

Science minister Patrick Vallance says Department of Health will fund the extra spending out of its existing budget ...

New figures show that the total cost of prescription medicines to the NHS in England reached a new high of £17.2 billion in the financial year 2021 -2022, according to a new independent report by the ...

This change has come from wider government concerns over protecting UK-based pharmaceutical manufacturing, and now from ...

The first drug to slow the progression of early stage Alzheimer’s will not be available on the NHS in England because health assessment body NICE says the benefits “are too small to justify the costs” ...

The National Institute for Health and Care Excellence (NICE) has ruled in its final draft guidance that two innovate drugs – olipudase alfa for acid sphingomyelinase deficiency (ASMD) Niemann-Pick ...

Weight-loss drug tirzepatide (Mounjaro) is due to be rolled out to 1.6 million patients over the next 12 years under NHS plans submitted to the National Institute for Health and Care (NICE). With NICE ...

Two breakthrough drugs that slow the progression of Alzheimer’s disease have been refused for use on the NHS in a blow to thousands of patients. Lecanemab and donanemab slow down the decline in ...

Add Yahoo as a preferred source to see more of our stories on Google. The NHS must pay more towards new drug development to help cut prices for Americans, a major US pharmaceutical giant has said.

"The government has claimed that the deal will only cost around £1 billion per year, but the UK's new commitment to double ...